YU49170B - Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena - Google Patents

Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena

Info

Publication number
YU49170B
YU49170B YU46794A YU46794A YU49170B YU 49170 B YU49170 B YU 49170B YU 46794 A YU46794 A YU 46794A YU 46794 A YU46794 A YU 46794A YU 49170 B YU49170 B YU 49170B
Authority
YU
Yugoslavia
Prior art keywords
raloxyphen
pharmaceutical formulation
formulation based
raloxifene
pth
Prior art date
Application number
YU46794A
Other languages
English (en)
Serbo-Croatian (sh)
Other versions
YU46794A (sh
Inventor
Mary Janet Hock
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU46794A publication Critical patent/YU46794A/sh
Publication of YU49170B publication Critical patent/YU49170B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
YU46794A 1993-07-22 1994-07-21 Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena YU49170B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9648093A 1993-07-22 1993-07-22

Publications (2)

Publication Number Publication Date
YU46794A YU46794A (sh) 1997-03-07
YU49170B true YU49170B (sh) 2004-05-12

Family

ID=22257534

Family Applications (1)

Application Number Title Priority Date Filing Date
YU46794A YU49170B (sh) 1993-07-22 1994-07-21 Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena

Country Status (29)

Country Link
US (1) US5510370A (en:Method)
EP (1) EP0635270B1 (en:Method)
JP (1) JPH0769920A (en:Method)
KR (1) KR100306852B1 (en:Method)
CN (1) CN1105577C (en:Method)
AT (1) ATE189959T1 (en:Method)
AU (1) AU686628B2 (en:Method)
BR (1) BR9402902A (en:Method)
CA (1) CA2128376A1 (en:Method)
CY (1) CY2192B1 (en:Method)
CZ (1) CZ289648B6 (en:Method)
DE (1) DE69423146T2 (en:Method)
DK (1) DK0635270T3 (en:Method)
ES (1) ES2142380T3 (en:Method)
GR (1) GR3033492T3 (en:Method)
HU (1) HU219382B (en:Method)
IL (1) IL110350A (en:Method)
MY (1) MY124311A (en:Method)
NO (1) NO942708L (en:Method)
NZ (2) NZ280040A (en:Method)
PE (1) PE14595A1 (en:Method)
PH (1) PH30686A (en:Method)
PL (1) PL304348A1 (en:Method)
PT (1) PT635270E (en:Method)
RU (1) RU2155042C2 (en:Method)
SI (1) SI0635270T1 (en:Method)
TW (1) TW303299B (en:Method)
YU (1) YU49170B (en:Method)
ZA (1) ZA945249B (en:Method)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5578613A (en) * 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5502074A (en) * 1994-08-22 1996-03-26 Eli Lilly And Company Benzothiophenes for bone healing and fracture repair
JP2001503728A (ja) * 1994-09-09 2001-03-21 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症治療用のエストロゲン及び副甲状腺ホルモン
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
ZA96897B (en) * 1995-02-06 1997-08-05 Lilly Co Eli Methods of inhibiting effects of IL-6.
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
AU761274B2 (en) * 1996-01-29 2003-05-29 Schering Aktiengesellschaft Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1016412A4 (en) * 1997-07-22 2001-05-02 Chugai Pharmaceutical Co Ltd DENTISTRY WITH PTH
JP2001519384A (ja) * 1997-10-14 2001-10-23 イーライ・リリー・アンド・カンパニー 骨の構築と維持のための方法
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
WO2000019823A1 (en) * 1998-10-07 2000-04-13 The Board Of Trustees Of The University Of Arkansas Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
US6416737B1 (en) 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
ATE314822T1 (de) * 2000-10-10 2006-02-15 Microchips Inc Mikrochip-reservoir-vorrichtungen mit drahtloser übertragung von energie und daten
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
SI1460969T1 (sl) * 2001-11-29 2008-10-31 Gtx Inc Preprečevanje in zdravljenje s pomanjkanjem androgena inducirane osteoporoze
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
UA85374C2 (en) * 2002-06-13 2009-01-26 Уайт bazedoxifene treatment regimen
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US20050272717A1 (en) * 2004-01-13 2005-12-08 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
MXPA06013168A (es) * 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US7488316B2 (en) * 2005-01-25 2009-02-10 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
US7691105B2 (en) * 2005-09-26 2010-04-06 Depuy Spine, Inc. Tissue augmentation, stabilization and regeneration technique
US20070088436A1 (en) 2005-09-29 2007-04-19 Matthew Parsons Methods and devices for stenting or tamping a fractured vertebral body
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20070168041A1 (en) * 2006-01-17 2007-07-19 Sudhakar Kadiyala Method and instruments for intervertebral disc augmentation through a pedicular approach
ES2930183T3 (es) * 2006-12-29 2022-12-07 Ossifi Mab Llc Métodos para alterar el crecimiento óseo mediante la administración del antagonista o agonista de Sost o Wise
EP2136850B1 (en) 2007-04-13 2012-02-01 Kuros Biosurgery AG Polymeric tissue sealant
US8241294B2 (en) * 2007-12-19 2012-08-14 Depuy Spine, Inc. Instruments for expandable corpectomy spinal fusion cage
US8241363B2 (en) * 2007-12-19 2012-08-14 Depuy Spine, Inc. Expandable corpectomy spinal fusion cage
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US8876905B2 (en) * 2009-04-29 2014-11-04 DePuy Synthes Products, LLC Minimally invasive corpectomy cage and instrument
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
CN102844033A (zh) * 2010-04-16 2012-12-26 诺华有限公司 提高植入物骨结合的方法和组合物
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
JP6683628B2 (ja) * 2014-06-04 2020-04-22 シーダーズ−サイナイ メディカル センター 脊椎圧迫骨折の非外科的修復のための方法
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE4039656A1 (de) * 1990-12-12 1992-06-17 Bissendorf Peptide Gmbh Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
HU219382B (en) 2001-03-28
RU2155042C2 (ru) 2000-08-27
CA2128376A1 (en) 1995-01-23
KR100306852B1 (ko) 2001-11-30
RU94027680A (ru) 1996-11-10
NZ264027A (en) 1996-03-26
CZ173394A3 (en) 1995-04-12
ATE189959T1 (de) 2000-03-15
AU6757794A (en) 1995-02-02
NO942708L (no) 1995-01-23
CN1105882A (zh) 1995-08-02
ES2142380T3 (es) 2000-04-16
SI0635270T1 (en) 2000-08-31
HK1013800A1 (en) 1999-09-10
JPH0769920A (ja) 1995-03-14
US5510370A (en) 1996-04-23
CN1105577C (zh) 2003-04-16
BR9402902A (pt) 1995-04-11
NZ280040A (en) 1997-06-24
MY124311A (en) 2006-06-30
PE14595A1 (es) 1995-06-01
PT635270E (pt) 2000-07-31
ZA945249B (en) 1996-01-18
TW303299B (en:Method) 1997-04-21
DE69423146D1 (de) 2000-04-06
KR950002785A (ko) 1995-02-16
CY2192B1 (en) 2002-11-08
DK0635270T3 (da) 2000-06-05
CZ289648B6 (cs) 2002-03-13
IL110350A (en) 2002-02-10
EP0635270A1 (en) 1995-01-25
EP0635270B1 (en) 2000-03-01
YU46794A (sh) 1997-03-07
DE69423146T2 (de) 2000-09-21
PL304348A1 (en) 1995-01-23
HU9402157D0 (en) 1994-09-28
IL110350A0 (en) 1994-10-21
GR3033492T3 (en) 2000-09-29
NO942708D0 (no) 1994-07-19
PH30686A (en) 1997-09-16
HUT67945A (en) 1995-05-29
AU686628B2 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
YU49170B (sh) Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena
GB8912389D0 (en) Laser apparatus for medical treatment
BG46024A1 (en) Method and device for treatment of bone patology
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
PL303937A1 (en) Application of an antiestrogen compound and pharmaceutical agent
IL114683A0 (en) Combination treatment for inhibiting bone loss
IL98258A0 (en) Composition for treating impotence containing doxazosin,amlodipine,or u.k.52,046
CY1513A (en) Benzothiphene derivatives as bronchodilators
NZ247123A (en) Method for treating osteoporosis and igf-1 composition containing bone antiresorptive active substance
EP0428876A3 (en) Method for the prevention and treatment of bovine mastitis
PH31098A (en) Melatonin derivatives for use in treating sleep disorders.
PT76247A (en) Process for preparing antiinflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes and of pharmaceutical compositions containing the same
HU9502202D0 (en) A novel osteoblastic proliferative factor
AU639693B2 (en) Laser apparatus for treating bone and tooth tissue
GB8907188D0 (en) Pharmaceutical composition and method for treating psoriasis
SU1572587A1 (ru) Уctpoйctbo для octeocиhteзa шeйkи бeдpehhoй koctи